Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

136.97 +2.01 (+1.49%)
Streaming Delayed Price Updated: 12:16 PM EDT, Aug 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,652,230
Open 137.33
Bid (Size) 136.95 (1)
Ask (Size) 136.99 (1)
Prev. Close 134.96
Today's Range 136.32 - 138.49
52wk Range 86.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.29%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages
Sesame introduces an affordable weight loss program with compounded versions of Wegovy amid supply shortages. The program provides a $249 monthly alternative to expensive obesity treatments. 
Via Benzinga

Performance

YTD
+34.14%
+34.14%
1 Month
+2.85%
+2.85%
3 Month
+2.19%
+2.19%
6 Month
+13.26%
+13.26%
1 Year
+48.07%
+48.07%

More News

Read More
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
Via Benzinga
Topics Economy
Exposures Supply Chain
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?
Via The Motley Fool
Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,900 Today
Via Benzinga
A Glimpse Into The Expert Outlook On Novo Nordisk Through 8 Analysts
Via Benzinga
Unpacking the Latest Options Trading Trends in Novo Nordisk
Via Benzinga
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
Via Benzinga
Telehealth Firm Hims & Hers Health Rides High On Demand for Copycat Weight Loss Drugs Amid Supply Shortages
Via Benzinga
Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond
Via The Motley Fool
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
Via The Motley Fool
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
Via The Motley Fool
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
Via The Motley Fool
Is Madrigal Pharmaceuticals Stock a Buy?
Via The Motley Fool
3 Fantastic Growth Stocks to Buy in August
Via The Motley Fool
Could Viking Therapeutics Become the Next Novo Nordisk?
Via The Motley Fool
Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
Via Benzinga
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Via Benzinga
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
Via The Motley Fool
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
Via The Motley Fool
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
Via Investor's Business Daily
Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors?
Via The Motley Fool
Topics Earnings
Exposures Financial
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
Via Benzinga
Exposures Product Safety
Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.